Irbesartan Clonmel

Irbesartan, the active ingredient in Irbesartan Clonmel, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and to protect kidney function in patients with diabetes‑related kidney disease.

GNH USA supplies Irbesartan Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an ARB that acts on the renin‑angiotensin system to control blood pressure and renal outcomes.

Hypertension: lowers systolic and diastolic pressure, reducing the risk of cardiovascular events. Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes, helping preserve renal function.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Upper respiratory tract infection - Nausea

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Hyperkalemia (elevated blood potassium) - Acute renal impairment or failure - Hepatic injury (elevated liver enzymes or hepatitis)

Patients should be monitored for safety and appropriate use. - Blood pressure monitoring: check regularly to ensure therapeutic effect. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with severe liver disease. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines; clinical judgment is required.

Major Interactions (Avoid): - Concomitant aliskiren in diabetic patients: increased risk of renal dysfunction. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hyperkalemia and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous potassium elevation. - High‑dose NSAIDs in patients with compromised renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium concentrations. - Cyclosporine or tacrolimus: can raise serum creatinine. - NSAIDs (regular dose): may reduce antihypertensive effect. - Thiazide diuretics: may enhance hypotensive response.